O	3	12	Incidence
O	13	16	and
O	17	28	progression
O	29	34	rates
O	35	37	of
B-Disease	38	41	age
I-Disease	41	42	-
I-Disease	42	49	related
I-Disease	50	61	maculopathy
O	61	62	:
O	63	66	the
O	67	76	Rotterdam
O	77	82	Study

O	84	91	Purpose
O	91	92	:
O	93	95	To
O	96	104	describe
O	105	108	the
O	109	118	incidence
O	119	123	rate
O	124	126	of
B-Disease	127	130	age
I-Disease	130	131	-
I-Disease	131	138	related
I-Disease	139	146	macular
I-Disease	147	159	degeneration
O	160	161	(
B-Disease	161	164	AMD
O	164	165	)
O	166	169	and
O	170	173	the
O	174	185	progression
O	186	191	rates
O	192	194	of
B-Disease	195	200	early
I-Disease	201	207	stages
I-Disease	208	210	of
I-Disease	211	214	age
I-Disease	214	215	-
I-Disease	215	222	related
I-Disease	223	234	maculopathy
O	235	236	(
B-Disease	236	239	ARM
O	239	240	)
O	240	241	,
O	242	245	and
O	246	248	to
O	249	254	study
O	255	258	the
O	259	268	hierarchy
O	269	271	of
B-Anatomy	272	278	fundus
O	279	287	features
O	288	292	that
O	293	302	determine
O	303	314	progression
O	314	315	.

O	317	324	Methods
O	324	325	:
O	326	327	A
O	328	333	group
O	334	336	of
O	337	341	4953
O	342	350	subjects
B-Characteristic	351	355	aged
I-Characteristic	356	358	55
I-Characteristic	359	364	years
I-Characteristic	365	368	and
I-Characteristic	369	374	older
I-Characteristic	375	381	living
I-Characteristic	382	384	in
I-Characteristic	385	394	Rotterdam
O	394	395	,
B-Characteristic	396	399	The
I-Characteristic	400	411	Netherlands
O	411	412	,
O	413	416	was
O	417	424	studied
O	425	427	at
O	428	436	baseline
O	437	440	and
O	441	443	at
O	444	445	2
O	445	446	-
O	446	450	year
O	451	457	follow
O	457	458	-
O	458	460	up
O	461	463	to
O	464	473	determine
O	474	477	the
O	478	487	incidence
O	488	490	of
B-Disease	491	502	neovascular
I-Disease	503	506	and
I-Disease	507	515	atrophic
I-Disease	516	519	AMD
O	519	520	.

O	521	522	A
O	523	531	subgroup
O	532	534	of
O	535	539	1244
O	540	548	subjects
O	549	552	was
O	553	560	studied
O	561	564	for
O	565	576	progression
O	577	579	of
B-Disease	580	585	early
I-Disease	586	592	stages
I-Disease	593	595	of
I-Disease	596	599	ARM
O	599	600	.

B-Diagnostic_tool	601	607	Fundus
I-Diagnostic_tool	608	622	transparencies
O	623	627	were
O	628	634	graded
O	635	638	for
O	639	647	features
O	648	650	of
B-Disease	651	654	ARM
O	655	660	using
O	661	664	the
B-Classification_system	665	678	International
I-Classification_system	679	693	Classification
I-Classification_system	694	700	System
O	700	701	.

B-Disease	702	705	ARM
O	706	709	was
O	710	720	stratified
O	721	723	in
O	724	728	four
O	729	738	exclusive
O	739	745	stages
O	745	746	,
O	747	756	according
O	757	759	to
O	760	764	type
O	765	767	of
B-Symptom	768	774	drusen
O	775	778	and
O	779	787	presence
O	788	790	of
B-Symptom	791	801	pigmentary
I-Symptom	802	816	irregularities
O	816	817	.

O	819	826	Results
O	826	827	:
O	828	831	The
O	832	839	overall
O	840	841	2
O	841	842	-
O	842	846	year
O	847	857	cumulative
O	858	867	incidence
O	868	870	of
B-Disease	871	874	AMD
O	875	878	was
O	879	880	0
O	880	881	.
O	881	882	2
O	882	883	%
O	883	884	,
O	885	895	increasing
O	896	898	to
O	899	900	1
O	900	901	.
O	901	902	8
O	902	903	%
O	904	906	in
O	907	915	subjects
O	916	918	of
B-Characteristic	919	921	85
I-Characteristic	922	927	years
I-Characteristic	928	931	and
I-Characteristic	932	937	older
I-Characteristic	937	938	.

O	939	941	Of
O	942	947	those
O	948	950	in
O	951	954	the
O	955	960	early
O	961	967	stages
O	967	968	,
O	969	972	one
O	973	979	fourth
O	980	986	showed
O	987	998	progression
O	999	1001	to
O	1002	1003	a
O	1004	1008	more
O	1009	1015	severe
O	1016	1021	stage
O	1021	1022	.

O	1023	1026	The
O	1027	1031	most
O	1032	1041	important
O	1042	1052	predictors
O	1053	1056	for
O	1057	1068	progression
O	1069	1073	were
B-Symptom	1074	1078	more
I-Symptom	1079	1083	than
I-Symptom	1084	1086	10
I-Symptom	1086	1087	%
I-Symptom	1088	1090	of
I-Symptom	1091	1098	macular
I-Symptom	1099	1103	area
I-Symptom	1104	1111	covered
I-Symptom	1112	1114	by
I-Symptom	1115	1121	drusen
O	1122	1123	(
O	1123	1127	odds
O	1128	1133	ratio
O	1134	1135	[
O	1135	1137	OR
O	1137	1138	]
O	1139	1140	5
O	1140	1141	.
O	1141	1142	7
O	1142	1143	,
O	1144	1146	95
O	1146	1147	%
O	1148	1158	confidence
O	1159	1167	interval
O	1168	1169	[
O	1169	1171	CI
O	1171	1172	]
O	1173	1174	2
O	1174	1175	.
O	1175	1176	9
O	1176	1177	-
O	1177	1179	11
O	1179	1180	.
O	1180	1181	3
O	1181	1182	)
O	1182	1183	,
O	1184	1192	presence
O	1193	1195	of
B-Symptom	1196	1210	depigmentation
O	1211	1212	(
O	1212	1214	OR
O	1215	1216	4
O	1216	1217	.
O	1217	1218	0
O	1218	1219	,
O	1220	1222	95
O	1222	1223	%
O	1224	1226	CI
O	1227	1228	2
O	1228	1229	.
O	1229	1230	5
O	1230	1231	-
O	1231	1232	6
O	1232	1233	.
O	1233	1234	4
O	1234	1235	)
O	1235	1236	,
O	1237	1240	and
B-Symptom	1241	1258	hyperpigmentation
O	1259	1260	(
O	1260	1262	OR
O	1263	1264	3
O	1264	1265	.
O	1265	1266	4
O	1266	1267	,
O	1268	1270	95
O	1270	1271	%
O	1272	1274	CI
O	1275	1276	2
O	1276	1277	.
O	1277	1278	1
O	1278	1279	-
O	1279	1280	5
O	1280	1281	.
O	1281	1282	4
O	1282	1283	)
O	1283	1284	.

O	1286	1297	Conclusions
O	1297	1298	:
O	1299	1302	The
O	1303	1312	incidence
O	1313	1315	of
B-Disease	1316	1319	AMD
O	1320	1327	appears
O	1328	1330	to
O	1331	1333	be
O	1334	1339	lower
O	1340	1342	in
B-Characteristic	1343	1346	The
I-Characteristic	1347	1358	Netherlands
O	1359	1363	than
O	1364	1366	in
O	1367	1370	the
B-Characteristic	1371	1377	United
I-Characteristic	1378	1384	States
O	1384	1385	.

O	1386	1397	Progression
O	1398	1400	of
B-Disease	1401	1406	early
I-Disease	1407	1410	ARM
I-Disease	1411	1417	stages
O	1418	1424	occurs
O	1425	1427	in
O	1428	1429	a
O	1430	1438	distinct
O	1439	1446	pattern
O	1447	1449	at
O	1450	1451	a
O	1452	1458	stable
O	1459	1463	rate
O	1463	1464	,
O	1465	1469	with
O	1470	1471	a
B-Symptom	1472	1477	large
I-Symptom	1478	1482	area
I-Symptom	1483	1485	of
I-Symptom	1486	1492	drusen
O	1493	1496	and
O	1497	1505	presence
O	1506	1508	of
B-Symptom	1509	1519	pigmentary
I-Symptom	1520	1527	changes
O	1528	1530	as
O	1531	1534	the
O	1535	1539	most
O	1540	1549	important
O	1550	1560	predictors
O	1560	1561	.
